查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1527174

粪钙卫蛋白测试市场 - 全球产业规模、份额、趋势、机会和预测，按检测类型、适应症、最终用户、地区和竞争细分，2019-2029F

Fecal Calprotectin Test Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Assay Type, By Indication, By End User, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2023年，全球粪便钙卫蛋白测试市场价值为2.7565亿美元，预计到2029年将达到4.0564亿美元，预测期内复合年增长率为6.85%。钙卫蛋白粪便测试，也称为粪便钙卫蛋白测试，透过评估粪便样本中钙卫蛋白的存在来评估肠道发炎。钙卫蛋白是白血球中的一种蛋白质，当肠道发炎时，粪便中的钙卫蛋白会增加。此测试是胃肠道发炎的高度敏感标记，有助于区分发炎性肠道疾病 (IBD) 和肠躁症 (IBS)。它用于 IBD 患者的诊断、监测疾病活动性、指导治疗以及预测復发或术后復发。对于已经诊断出患有 IBD 的人来说，该测试有助于追踪发炎程度并评估治疗效果。酵素连结免疫吸附测定 (ELISA) 因其准确性和可靠性而成为使用最广泛的方法，而侧向层析免疫测定可快速提供结果，并且适合现场护理环境。一些诊断测试的高成本可能会阻碍其广泛使用，并且遵守不同的监管标准也带来了挑战。儘管市场竞争激烈，既有老牌企业，也有新兴企业，但全球医疗保健支出的增加正在推动先进诊断测试的成长。由于疾病盛行率上升、医疗保健投资增加以及持续的技术进步，粪便钙卫蛋白测试市场预计将进一步扩大。测试方法的创新和更广泛的市场覆盖范围预计将推动持续成长和采用。

市场概况
预测期 2026-2030
2023 年市场规模 27565万美元
2029 年市场规模 40564万美元
2024-2029 年复合年增长率 6.85%
成长最快的细分市场 发炎性肠道疾病（IBD）
最大的市场 北美洲

主要市场驱动因素

发炎性肠道疾病的盛行率不断增加

对非侵入性诊断工具的需求不断增长

主要市场挑战

测试准确度的变化

意识和教育有限

主要市场趋势

专注于早期诊断与个人化医疗

细分市场洞察

分析类型见解

适应症见解

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：COVID-19 对全球粪钙卫蛋白测试市场的影响

第 5 章：全球粪便钙卫蛋白测试市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依测定类型（酵素连结免疫吸附测定法 (ELISA)、酵素萤光免疫测定和定量免疫色谱）
    • 依适应症（发炎性肠道疾病 (IBD) 诊断、大肠直肠癌、乳糜泻等）
    • 按最终使用者（医院、诊断实验室、学术和研究机构等）
    • 按地区
    • 按公司划分 (2023)
  • 市场地图

第 6 章：亚太地区粪便钙卫蛋白测试市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按检测类型
    • 按指示
    • 按最终用户
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 澳洲
    • 日本
    • 韩国

第 7 章：欧洲粪便钙卫蛋白测试市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按检测类型
    • 按指示
    • 按最终用户
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 西班牙
    • 义大利
    • 英国

第 8 章：北美粪钙卫蛋白测试市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按检测类型
    • 按指示
    • 按最终用户
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 9 章：南粪钙卫蛋白测试市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按检测类型
    • 按指示
    • 按最终用户
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西粪便钙卫蛋白测试
    • 阿根廷粪便钙卫蛋白测试
    • 哥伦比亚粪便钙卫蛋白测试

第 10 章：中东和非洲粪钙卫蛋白测试市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按检测类型
    • 按指示
    • 按最终用户
    • 按国家/地区
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋粪便钙卫蛋白测试市场前景
      • 市场规模及预测
        • 按价值
      • 市占率及预测
        • 按检测类型
        • 按指示
        • 按最终用户

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 最近的发展
  • 产品发布
  • 併购

第 13 章：全球粪钙卫蛋白测试市场：SWOT 分析

第 14 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第15章：竞争格局

  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd
  • Boditech Med Inc.
  • Abbexa Ltd.
  • Elabscience Bionovation Inc.
  • Epitope Diagnostics, Inc.
  • R-Biopharm AG
  • Sentinel Ch SpA
  • LifeSpan BioSciences, Inc

第 16 章：策略建议

第17章调查会社について・免责事项

简介目录
Product Code: 24527

Global Fecal Calprotectin Test Market was valued at USD 275.65 Million in 2023 and and is expected to reach USD 405.64 Million by 2029 with a CAGR of 6.85% during the forecast period. The calprotectin stool test, also known as the fecal calprotectin test, evaluates the presence of calprotectin protein in a stool sample to assess intestinal inflammation. Calprotectin, a protein found in white blood cells, increases in the stool when there is gut inflammation. This test is a highly sensitive marker for gastrointestinal inflammation and helps differentiate between inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). It is used for diagnosing, monitoring disease activity, guiding treatment, and predicting relapses or post-operative recurrence in IBD patients. For those already diagnosed with IBD, the test helps track inflammation levels and evaluate treatment efficacy. The Enzyme-Linked Immunosorbent Assay (ELISA) is the most widely used method due to its accuracy and reliability, while Lateral Flow Immunoassays offer rapid results and are suitable for point-of-care settings. The high cost of some diagnostic tests can hinder widespread use, and compliance with diverse regulatory standards poses challenges. Despite a competitive market with established and emerging players, the global increase in healthcare expenditure is driving the growth of advanced diagnostic tests. The fecal calprotectin test market is anticipated to expand further due to rising disease prevalence, greater healthcare investments, and ongoing technological advancements. Innovations in testing methods and broader market reach are expected to fuel continued growth and adoption.

Market Overview
Forecast Period2026-2030
Market Size 2023USD 275.65 Million
Market Size 2029USD 405.64 Million
CAGR 2024-20296.85%
Fastest Growing SegmentInflammatory Bowel Disease (IBD)
Largest MarketNorth America

Key Market Drivers

Increasing Prevalence of Inflammatory Bowel Disease

The incidence and prevalence of inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, have significantly increased. In 2023, global cases of ulcerative colitis were estimated at 5 million, with a rising incidence reported worldwide according to a study by *The Lancet*. In the U.S., the prevalence of IBD is estimated to be between 2.4 and 3.1 million, varying across different populations as reported by the Centers for Disease Control and Prevention (CDC). This expanding patient base necessitates regular monitoring and management, driving up the demand for diagnostic tools such as fecal calprotectin tests.

Regular testing is crucial for IBD patients to monitor disease activity, evaluate treatment effectiveness, and detect potential relapses. The fecal calprotectin test plays a vital role in these processes, leading to increased market demand. Effective management of IBD relies on frequent assessment of inflammation levels to customize treatment plans, and the fecal calprotectin test provides essential data for personalized care.

As IBD prevalence grows, healthcare systems are investing more in specialized diagnostic tools and treatments, which supports the adoption of advanced tests like fecal calprotectin. Early and accurate diagnosis enhances patient outcomes, and fecal calprotectin tests are integral to the diagnostic process, contributing to market growth. Ongoing research into IBD drives innovation, leading to the development of more precise and efficient fecal calprotectin assays. This research supports continued market expansion, as the rising prevalence of IBD fuels the ongoing demand for effective diagnostic tools.

Rising Demand for Non-invasive Diagnostic Tools

Non-invasive diagnostic tests, such as fecal calprotectin assays, are increasingly favored by patients for their convenience and comfort compared to invasive procedures like endoscopies or biopsies. These tests reduce the risk of complications and discomfort associated with more invasive methods, making them more appealing to both patients and healthcare providers. A study published in Frontline Gastroenterology in May 2024 by researchers at the Birmingham HIHR Biomedical Research Centre, University of Birmingham, examined a new protocol designed to expedite IBD diagnosis for patients referred to the Birmingham IBD inception pathway between January 2021 and August 2023. This rapid-access clinic aims to accelerate the diagnosis process for patients over 16 with suspected IBD.

Non-invasive tests can be performed in diverse settings, including at home or in primary care facilities, enhancing accessibility for patients who might otherwise encounter barriers with invasive procedures. As patients increasingly seek convenient testing options that fit their lifestyles, fecal calprotectin tests offer an easy way to monitor gastrointestinal health without the need for extensive clinical visits. For chronic conditions like IBD, non-invasive tests enable regular monitoring and management, promoting consistent testing and follow-up care. A study published in Nature in July 2024 explored the diagnostic capabilities of near-infrared spectroscopy and aquaphotomics for IBD and its variants. The research used blood plasma and saliva samples analyzed with techniques such as Principal Component Analysis and Support Vector Machine, achieving 100% accuracy in distinguishing between healthy individuals and those with IBD, as well as between different types of IBD. This study highlighted the potential of non-invasive methods to monitor biofluids and changes in their spectral patterns, providing valuable insights into IBD.

A new PET radiotracer, detailed in the November 2023 issue of the *Journal of Nuclear Medicine*, creates comprehensive inflammation maps of the gastrointestinal tract. This tool targets the IBD biomarker IL12/23p40, offering a minimally invasive approach to detect and stage IBD, thereby guiding treatment decisions. Ongoing research and advancements in non-invasive diagnostic technologies enhance the accuracy and reliability of tests like fecal calprotectin assays, driving their adoption in clinical practice. As non-invasive testing gains traction, the market for these diagnostic tools expands, presenting opportunities for further growth and innovation.

Key Market Challenges

Variability in Test Accuracy

Variability in test accuracy represents a major challenge for the fecal calprotectin test market. Inconsistent results can undermine the diagnostic reliability of these tests, potentially diminishing clinician confidence and impacting patient outcomes. Differences in testing protocols, sample handling, and laboratory practices contribute to this variability. The absence of standardization among laboratories further exacerbates discrepancies in results. Ensuring accurate test outcomes depends heavily on proper stool sample collection, handling, and storage; any issues in these areas can compromise test performance and reliability.

Regulatory authorities demand high accuracy and consistency for diagnostic tests. Variability in test accuracy can attract increased scrutiny and regulatory hurdles, potentially delaying market approval and adoption. Additionally, inconsistent results can erode trust among healthcare providers and patients, making it essential to maintain high and consistent accuracy to foster confidence in the test.

The need for additional follow-up testing or confirmatory procedures due to variability can increase overall healthcare costs and affect the economic feasibility of using fecal calprotectin tests. Addressing this challenge requires ongoing research and development to improve test accuracy and reliability, implementing standardized testing procedures, and enforcing rigorous quality control measures to ensure consistent performance across different settings and laboratories.

Limited Awareness and Education

Limited awareness of the benefits and availability of fecal calprotectin tests among both healthcare providers and patients can result in reduced adoption rates. A lack of education and training for healthcare professionals on the use and interpretation of these tests can hinder their effective implementation, potentially leading to suboptimal use and missed diagnostic opportunities. This insufficient awareness can impede the market growth and expansion of fecal calprotectin tests, as widespread recognition and understanding are essential for market penetration.

Patients who do not know about the test or its importance in managing conditions such as inflammatory bowel disease (IBD) cannot seek or follow through with testing recommendations. Enhancing patient education is vital for improving both engagement and adherence. Additionally, variations in clinical guidelines and diagnostic protocols across different regions or institutions can result in inconsistent use of fecal calprotectin tests. Standardizing these guidelines and protocols can facilitate greater adoption. Financial constraints in certain healthcare settings can also impact the adoption of new diagnostic tests. Addressing these financial barriers through cost-effective solutions and clearly demonstrating the value of fecal calprotectin tests can help overcome this challenge.

Key Market Trends

Focus on Early Diagnosis and Personalized Medicine

The emphasis on early disease detection is increasing, aiming to enable timely interventions. Fecal calprotectin tests are increasingly utilized for the early identification of inflammation, particularly in inflammatory bowel disease (IBD), where early diagnosis and management are crucial. In 2023, Meta-Spec, an AI-driven diagnostic tool developed collaboratively by researchers in China and the United States, evaluates a range of factors beyond microbiome data. This approach offers a more comprehensive and nuanced disease detection and prediction model compared to existing options, considering aspects such as the frequency of vivid dreams and the quality of bowel movements.

The move towards personalized medicine focuses on customizing treatment strategies to individual patient profiles. Fecal calprotectin tests provide critical insights into disease activity, allowing healthcare providers to tailor treatment plans to meet each patient's specific needs. These tests are increasingly being integrated into personalized care approaches, offering a reliable, non-invasive method for continuous monitoring of disease activity and treatment effectiveness. Prometheus Laboratories Inc. partnered with Takeda Pharmaceutical Company Limited to introduce CDPATH, an innovative prognostic tool for Crohn's disease (CD) patients. CDPATH is designed to work alongside clinical assessments to evaluate an adult patient's risk for severe CD complications, such as bowel strictures or internal penetrating disease, within three years. As the focus on early diagnosis and personalized medicine intensifies, fecal calprotectin tests are becoming more standard in clinical practice for managing chronic gastrointestinal conditions. Institutions like The Ohio State University Wexner Medical Center's IBD Center are incorporating these tests into their diagnostic and treatment protocols, including a pediatric-to-adult transition program.

This shift towards personalized medicine aligns with patient-centric approaches that prioritize individual needs and preferences. Fecal calprotectin tests enhance patient engagement by offering a non-invasive method for ongoing health and disease monitoring.

Segmental Insights

Assay Type Insights

Based on Assay Type, the Enzyme Linked Immunosorbent Assay (ELISA) emerged as the dominating segment in the global market for Fecal Calprotectin Test in 2023. ELISA is widely recognized for its exceptional accuracy and reliability in detecting and quantifying specific biomarkers, such as calprotectin. This precision is critical for diagnosing and monitoring conditions like inflammatory bowel disease (IBD), where precise measurement of inflammation levels is vital. Due to its proven effectiveness and reliability, ELISA is extensively used in clinical laboratories. Its long-standing track record across various diagnostic applications has cemented its status as a trusted method, leading to its market dominance. ELISA's versatility allows it to be adapted for different assay types, including high-throughput screening and detailed biomarker quantification, making it suitable for a broad range of diagnostic applications, such as fecal calprotectin tests. The method's high sensitivity and specificity enable the detection of low calprotectin levels in stool samples, which is essential for early diagnosis and monitoring of diseases with minimal biomarker concentrations. The well-established and standardized procedures for conducting ELISA assays facilitate its integration into routine laboratory practices, further reinforcing its leading position in the market.

Indication Insights

Based on Indication Type, Inflammatory Bowel Disease (IBD) emerged as the fastest growing segment in the global market for Fecal Calprotectin Test during forecast period. The global rise in inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is increasing the demand for diagnostic tools such as fecal calprotectin tests. These tests are essential for diagnosing and monitoring IBD. Growing awareness among healthcare providers and patients is leading to earlier diagnoses and more frequent monitoring, with fecal calprotectin tests being central to this effort. Recent updates in clinical guidelines, such as those from the American Gastroenterological Association in 2023, stress the importance of fecal calprotectin for managing IBD, which is driving its greater adoption. Advances in testing technology have improved the accuracy and reliability of these tests, making them more attractive to healthcare providers. Expanding healthcare infrastructure, especially in emerging markets, is enhancing the accessibility and availability of these diagnostic tools, further accelerating growth in the IBD diagnosis segment.

Regional Insights

Based on Region, North America emerged as the dominant region in the Global Fecal Calprotectin Test Market in 2023. North America, particularly the United States and Canada, dedicates a significant portion of its GDP to healthcare. This substantial investment facilitates the acquisition and implementation of advanced diagnostic tools, such as fecal calprotectin tests. The region is equipped with a sophisticated healthcare infrastructure, including state-of-the-art diagnostic labs and hospitals, which supports the widespread adoption and integration of these tests. The high prevalence of inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, in North America further drives the demand for effective diagnostic solutions. According to Crohn's and Colitis Canada, the number of individuals with IBD in Canada is projected to rise from 322,600 in 2023 to 470,000 by 2035, highlighting the growing need for reliable diagnostic tools like fecal calprotectin tests for managing and monitoring these conditions.

There is also a strong level of awareness and education among healthcare providers and patients regarding gastrointestinal health and the benefits of fecal calprotectin tests, contributing to their increased adoption and use. In 2023, the American Gastroenterological Association issued new practice guidelines on the use of biomarkers in managing Crohn's disease. These guidelines provide 11 conditional recommendations to assist clinicians in utilizing various biomarkers, including fecal calprotectin, for both cross-sectional and longitudinal monitoring of disease activity in Crohn's disease patients. The region benefits from a robust regulatory framework that maintains high standards for medical and diagnostic products, supporting the approval and widespread use of fecal calprotectin tests.

Key Market Players

Thermo Fisher Scientific Inc.

Bio-Rad Laboratories, Inc.

F. Hoffmann-La Roche Ltd

Boditech Med Inc.

Abbexa Ltd.

Elabscience Bionovation Inc.

Epitope Diagnostics, Inc.

R-Biopharm AG

Sentinel Ch S.p.A.

LifeSpan BioSciences, Inc

Report Scope:

In this report, the Global Fecal Calprotectin Test Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Fecal Calprotectin Test Market, By Assay Type:

    Enzyme Linked Immunosorbent Assay (ELISA) Enzyme Fluoroimmunoassay Quantitative Immune-Chromatography

Fecal Calprotectin Test Market, By Indication:

    Inflammatory Bowel Disease (IBD) Diagnosis Colorectal Cancer Celiac Disease Others

Fecal Calprotectin Test Market, By End User:

    Hospitals Diagnostic Laboratories Academic and Research Institutes Others

Fecal Calprotectin Test Market, By Region:

    North America
    • United States
    • Canada
    • Mexico
    Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
    Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    South America
    • Brazil
    • Argentina
    • Colombia
    Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Fecal Calprotectin Test Market.

Available Customizations:

Global Fecal Calprotectin Test Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Impact of COVID-19 on Global Fecal Calprotectin Test Market

5. Global Fecal Calprotectin Test Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Assay Type (Enzyme Linked Immunosorbent Assay (ELISA), Enzyme Fluoroimmunoassay, and Quantitative Immune-Chromatography)
    • 5.2.2. By Indication (Inflammatory Bowel Disease (IBD) Diagnosis, Colorectal Cancer, Celiac Disease, and others)
    • 5.2.3. By End User (Hospitals, Diagnostic Laboratories, Academic and Research Institutes, and others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2023)
  • 5.3. Market Map

6. Asia Pacific Fecal Calprotectin Test Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Assay Type
    • 6.2.2. By Indication
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Fecal Calprotectin Test Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Assay Type
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By End User
    • 6.3.2. India Fecal Calprotectin Test Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Assay Type
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By End User
    • 6.3.3. Australia Fecal Calprotectin Test Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Assay Type
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By End User
    • 6.3.4. Japan Fecal Calprotectin Test Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Assay Type
        • 6.3.4.2.2. By Indication
        • 6.3.4.2.3. By End User
    • 6.3.5. South Korea Fecal Calprotectin Test Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Assay Type
        • 6.3.5.2.2. By Indication
        • 6.3.5.2.3. By End User

7. Europe Fecal Calprotectin Test Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Assay Type
    • 7.2.2. By Indication
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Fecal Calprotectin Test Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Assay Type
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany Fecal Calprotectin Test Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Assay Type
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By End User
    • 7.3.3. Spain Fecal Calprotectin Test Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Assay Type
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Fecal Calprotectin Test Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Assay Type
        • 7.3.4.2.2. By Indication
        • 7.3.4.2.3. By End User
    • 7.3.5. United Kingdom Fecal Calprotectin Test Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Assay Type
        • 7.3.5.2.2. By Indication
        • 7.3.5.2.3. By End User

8. North America Fecal Calprotectin Test Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Assay Type
    • 8.2.2. By Indication
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Fecal Calprotectin Test Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Assay Type
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By End User
    • 8.3.2. Mexico Fecal Calprotectin Test Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Assay Type
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By End User
    • 8.3.3. Canada Fecal Calprotectin Test Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Assay Type
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By End User

9. South America Fecal Calprotectin Test Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Assay Type
    • 9.2.2. By Indication
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Fecal Calprotectin Test Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Assay Type
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Fecal Calprotectin Test Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Assay Type
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Fecal Calprotectin Test Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Assay Type
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By End User

10. Middle East and Africa Fecal Calprotectin Test Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Assay Type
    • 10.2.2. By Indication
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Fecal Calprotectin Test Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Assay Type
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Fecal Calprotectin Test Market Outlook
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Assay Type
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Fecal Calprotectin Test Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Assay Type
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Fecal Calprotectin Test Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
  • 15.2. Bio-Rad Laboratories, Inc.
  • 15.3. F. Hoffmann-La Roche Ltd
  • 15.4. Boditech Med Inc.
  • 15.5. Abbexa Ltd.
  • 15.6. Elabscience Bionovation Inc.
  • 15.7. Epitope Diagnostics, Inc.
  • 15.8. R-Biopharm AG
  • 15.9. Sentinel Ch S.p.A.
  • 15.10. LifeSpan BioSciences, Inc

16. Strategic Recommendations

17. About Us & Disclaimer